enGene Therapeutics Inc. (ENGN)

The past six months have seen significant volatility and a substantial decline in enGene Therapeutics Inc.'s stock price, trending down by 75.25% from November 2025 to May 2026. In November 2025, the company reported updated preliminary data from the LEGEND pivotal cohort, showing a 63% complete response (CR) rate at any time and a 62% CR rate at 6 months for patients enrolled under an amended protocol. In December 2025, enGene reported full-year 2025 financial results, reiterating the promising preliminary LEGEND data and a cash runway into the second half of 2028. In April 2026, the company changed its name from enGene Holdings Inc. to enGene Therapeutics Inc. In May 2026, enGene announced updated interim results from the Phase 2 LEGEND pivotal cohort, showing a 54% complete response rate at any time, with weaker-than-expected durability. Following the May 2026 data release, the stock experienced a sharp decline, leading to multiple analyst downgrades and an investigation by a shareholder-rights law firm.

As a clinical-stage biotechnology company focused on developing genetic medicines, enGene Therapeutics Inc.'s products and services do not exhibit typical demand seasonality. The demand for its product is driven by the progression of clinical trials, regulatory approvals, and ultimately, the medical need for treatments for conditions like non-muscle invasive bladder cancer. These processes are continuous and are not subject to seasonal fluctuations in the way consumer goods or services might be.

enGene Therapeutics Inc. is a clinical-stage biotechnology company based in Montreal, Canada, focusing on genetic medicines within the healthcare sector. The company aims to mainstream gene therapy by delivering therapeutics to mucosal tissues and other organs to address diseases with high clinical needs. Its lead product candidate is detalimogene voraplasmid, a non-viral gene therapy for non-muscle invasive bladder cancer (NMIBC), being evaluated in the Phase 2 LEGEND trial. The therapy utilizes enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform and has received Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the FDA, and has been selected for the FDA's Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) Program.

enGene Therapeutics Inc. is headquartered in Saint-Laurent, Quebec, Canada. The LEGEND trial for detalimogene is actively enrolling patients with participating sites across the USA, Canada, Europe, and the Asia-Pacific region.

enGene Therapeutics Inc.'s brand reputation has been significantly impacted in the past year, particularly in May 2026, due to the updated interim results from its pivotal Phase 2 LEGEND trial. The announcement of weaker durability and lower complete response rates for its lead product candidate, detalimogene voraplasmid, led to a sharp decline in investor confidence and the company's stock price. This negative news triggered a wave of analyst downgrades and price target cuts from several prominent financial institutions. Furthermore, a shareholder-rights law firm initiated an investigation into the company, citing potential securities law concerns, which further tarnishes its reputation.

enGene Therapeutics Inc. has a significant institutional ownership presence, with 59 institutional owners and shareholders holding a total of 58,747,808 shares as of May 6, 2026. Major institutional owners include Fcpm Iii Services B.v., Perceptive Advisors Llc, and VR Adviser, LLC. Private equity firms collectively hold a substantial stake, around 38% of the company's shares, with Forbion Growth Opportunities Fund I Cooperatief Ua owning 10.15% of the company's shares.